# Exploratory Clinical Study of HRS-4642 Combined With Adebelimab in the Treatment of Advanced Pancreatic Cancer

> **NCT06427239** · PHASE1,PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 35 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** HRS-4642
- **DRUG:** Adebrelimab

## Key facts

- **NCT ID:** NCT06427239
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-29
- **Primary completion:** 2026-06
- **Final completion:** 2026-09
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2024-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06427239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06427239, "Exploratory Clinical Study of HRS-4642 Combined With Adebelimab in the Treatment of Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06427239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*